Voyager Therapeutics (VYGR) Equity Average (2015 - 2026)

Voyager Therapeutics has disclosed Equity Average across 12 years of filings, most recently posting $184.9 million for Q1 2026.

• Equity Average for Q1 2026 came in at $184.9 million, down 35.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.9 million (down 35.41% YoY), and the FY2025 annual result was $247.9 million, down 7.51% from the prior year.
• Equity Average came in at $184.9 million for Q1 2026 at Voyager Therapeutics, down from $208.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $338.2 million in Q2 2024 to a low of $68.0 million in Q2 2022.
• The 5-year median for Equity Average is $208.0 million (2025), against an average of $204.5 million.
• Across the five-year window, Equity Average plunged 44.89% in 2022 and jumped 205.91% in 2023, its largest moves.
• Voyager Therapeutics' Equity Average stood at $69.4 million in 2022, then surged by 197.13% to $206.3 million in 2023, then soared by 52.73% to $315.0 million in 2024, then tumbled by 33.99% to $208.0 million in 2025, then dropped by 11.1% to $184.9 million in 2026.
• The last three Equity Average figures came in at $184.9 million (Q1 2026), $208.0 million (Q4 2025), and $231.9 million (Q3 2025), per Business Quant data.